Healthcare Web Wire

Author: Elena Morales

Autoimmune Hepatitis Diagnosis and Treatment Market Outlook (2024 – 2032)
Market Insights: Growth in Autoimmune Hepatitis Diagnosis and Treatment

The market for autoimmune hepatitis diagnosis and treatment is projected to expand significantly, increasing from an estimated USD 14.03 billion in 2023 to over USD 19.15 billion by 2032. This growth reflects a steady compound annual growth rate (CAGR) of 3.3% during the forecast period, driven by rising demand for innovative treatment solutions and improved access to healthcare services globally.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5124

Recent Developments
- In January 2022, the U.S. Food and Drug Administration (FDA) granted approval to Lupin’s Tenofovir alafenamide tablets for the treatment of chronic hepatitis B viral infection, offering a new treatment option for patients battling this condition.
- In June 2022, Echosens partnered with Novo Nordisk to improve accessibility to non-invasive tests for diagnosing Non-Alcoholic Steatohepatitis (NASH), a liver condition. Their collaboration aims to expand NASH diagnoses, particularly for those with severe cases, and increase the number of diagnoses by four times by 2025.
Key Companies in the Autoimmune Hepatitis Diagnosis and Treatment Market

Abbott

Abbott is a global healthcare company that develops and manufactures a broad range of diagnostic tools, medical devices, and pharmaceutical products. Abbott offers diagnostic solutions for various liver conditions, including autoimmune hepatitis, and is known for its innovative approach to improving healthcare outcomes through accessible and accurate diagnostic tools.

Siemens Healthcare Private Limited

Siemens Healthcare, a division of Siemens AG, specializes in medical technology and healthcare solutions. The company develops imaging systems, diagnostic tests, and healthcare IT solutions. Siemens is a leader in diagnostics, including liver disease-related testing, and aims to improve the accuracy and efficiency of disease detection.

Beckman Coulter

Beckman Coulter, part of Danaher Corporation, is a global leader in providing laboratory instruments and reagents for various diagnostics, including autoimmune hepatitis. Their diagnostic platforms are widely used in healthcare facilities for testing and monitoring liver function, contributing to early disease detection and treatment planning.

Roche Diagnostics

Roche Diagnostics is a major player in the healthcare and diagnostics sector, offering a range of products for disease detection and management. The company is known for developing cutting-edge diagnostic tools, including tests for autoimmune hepatitis, and is committed to advancing healthcare through innovative diagnostic technologies.

Pfizer Inc.

Pfizer is one of the world’s largest pharmaceutical companies, involved in the development of drugs and vaccines for various diseases, including liver diseases. Pfizer has contributed to the autoimmune hepatitis treatment market with its portfolio of antiviral therapies and other liver disease treatments, focusing on advancing patient care through effective and targeted therapies.

GE Healthcare

GE Healthcare is a global leader in medical imaging and diagnostics, offering advanced imaging equipment and diagnostic tools used in the detection and management of liver conditions such as autoimmune hepatitis. GE Healthcare’s technologies play a vital role in improving diagnosis and treatment plans for patients with liver diseases.

Philips Healthcare

Philips Healthcare is a leading innovator in medical imaging and diagnostic technologies. The company focuses on providing non-invasive diagnostic tools for liver diseases, including autoimmune hepatitis. Philips’ solutions enhance the accuracy of disease detection and help in the management of chronic liver conditions through advanced imaging and monitoring systems.

Cadila Pharmaceuticals

Cadila Pharmaceuticals, also known as Zydus Cadila, is an Indian multinational pharmaceutical company that offers a wide range of medicines, including those for liver diseases. The company is engaged in the development of both diagnostic and therapeutic solutions for autoimmune hepatitis, with an emphasis on improving patient care and treatment options in emerging markets.

Bristol Myers Squibb Company

Bristol Myers Squibb (BMS) is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies, including those for autoimmune diseases. BMS is known for its immunotherapy treatments and plays a significant role in autoimmune hepatitis management through novel drug therapies aimed at modulating the immune response.

Merck & Co., Inc.

Merck & Co., Inc. is a leading global pharmaceutical company involved in the research and development of drugs for various diseases, including autoimmune hepatitis. Merck’s focus on immunology and liver diseases has led to the development of therapies aimed at managing autoimmune hepatitis and preventing disease progression.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/autoimmune-hepatitis-diagnosis-and-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5124

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 13, 2024
Hemato-Oncology Testing Market Size, Trends and Leading Companies Report
Hemato-Oncology Testing Market Size and Growth Outlook

The hemato-oncology testing market was valued at $3.17 billion in 2023 and is projected to experience substantial growth, reaching $9.78 billion by 2033. This expansion reflects a compound annual growth rate (CAGR) of 12.4% from 2024 to 2033.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5123

Insight Highlights
- Service Offerings: Services dominate the hemato-oncology testing market, making up a notable 58% share in 2023.
- Leukemia: As the most common blood cancer, leukemia held a 40% market share in 2023.
- PCR Technology: Polymerase chain reaction (PCR) remains the top testing method, commanding a 45% share in 2023, valued for its precision and efficiency.
- Non-Hodgkin Lymphoma (NHL): In 2024, NHL is estimated to represent around 4% of all cancer cases in the United States, with 80,620 new diagnoses and 20,140 deaths expected. Advances in early detection and treatment have contributed to reduced incidence and mortality rates.
Understanding Hemato-Oncology

Hemato-oncology focuses on diagnosing, treating, and managing blood cancers (like leukemia, lymphoma, and myeloma) and other blood disorders. Specialists in this field use various treatments, including chemotherapy, immunotherapy, targeted therapy, radiation therapy, and stem cell transplants, often working collaboratively with other experts to provide comprehensive care.

The Importance of Early Diagnosis

Detecting cancers and blood disorders early has numerous benefits. It allows for faster treatment initiation, often leading to better outcomes or even cures. Early detection also reduces the likelihood of the disease spreading, simplifies treatment, and enhances quality of life. For blood disorders, prompt treatment can prevent complications like anemia or bleeding issues. Additionally, early intervention can offer more treatment options and lower long-term healthcare costs by avoiding extensive, late-stage therapies.

Market Dynamics and Demand

As the need for cancer and blood disorder treatments grows, the hemato-oncology market expands. Pharmaceutical companies are investing in innovative drugs, while medical technology firms develop advanced diagnostic tools. This rising demand also increases the workload for specialists, who are vital for consultations, testing, and delivering therapies. The growing prevalence of these conditions drives advancements and improvements in the field, benefiting both patients and the broader healthcare industry.

Key Companies in the Hemato-Oncology Testing Market

The hemato-oncology testing market features several prominent players driving innovation and development. These companies provide advanced diagnostic solutions and technologies to improve the detection and management of blood cancers and related disorders:
- F. Hoffmann-La Roche Ltd.: A leader in healthcare and diagnostics, Roche offers cutting-edge tests and technologies for cancer and blood disorder detection.
- Qiagen N.V.: Renowned for its molecular diagnostic solutions, Qiagen plays a crucial role in advancing personalized medicine through innovative testing tools.
- Abbott: A global healthcare company offering comprehensive diagnostic solutions, including hematology and oncology testing.
- EntroGen, Inc.: Specializes in molecular diagnostics with a focus on genetic testing for cancer and blood disorders.
- Illumina Inc.: A pioneer in sequencing technologies, Illumina supports advancements in genetic and molecular testing for precise diagnostics.
- Thermo Fisher Scientific, Inc.: A major player in laboratory technologies and diagnostics, providing essential tools for hemato-oncology testing.
- Bio-Rad Laboratories: Offers a broad portfolio of diagnostic products, including molecular testing platforms for cancer detection.
- Sysmex Corporation: Known for its expertise in hematology systems, Sysmex develops innovative diagnostic solutions for blood-related conditions.
- Danaher Corporation: With its broad range of healthcare and diagnostics businesses, Danaher supports the hemato-oncology field through advanced technologies.
- Beckman Coulter, Inc.: A leader in clinical diagnostics, Beckman Coulter delivers reliable and efficient testing solutions for hematological conditions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/hemato-oncology-testing-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5123

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 13, 2024
Synovial Sarcoma Treatment Market Trends, Key Players and Growth Forecast
Synovial Sarcoma Treatment Market Overview
The synovial sarcoma treatment market was valued at USD 822.74 million in 2023 and is projected to grow to USD 1,144.84 million by 2033, with an estimated annual growth rate of 3.6% over the forecast period. Surgery continues to be the primary treatment method, holding a substantial 56% share of the market in 2023. North America leads the market, accounting for 41% of the total market share in 2023.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5121

Synovial sarcoma is a rare cancer that primarily affects young adults, usually under 30, and typically develops in the soft tissues around joints. Though it’s called “synovial” sarcoma, it doesn’t originate from the synovium. Early detection and treatment are vital, as it can spread quickly if untreated. Treatment often involves surgery, chemotherapy, and radiation.

The incidence of synovial sarcoma is rising, with about 800 to 1,000 cases annually. It’s caused by a chromosomal abnormality leading to fusion proteins that drive the cancer’s development.

New treatments are emerging, such as Catequentinib, which is being tested in a Phase 3 clinical trial. As the understanding of the disease grows, the demand for effective treatments is increasing.

Synovial Sarcoma Treatment Market Companies

Novartis: A global leader in healthcare, Novartis is known for its strong oncology portfolio, including targeted therapies and immunotherapies that may benefit patients with synovial sarcoma.

Eli Lilly and Company: Focused on advancing cancer treatments, Eli Lilly develops precision medicines and is exploring therapies that could target specific pathways involved in synovial sarcoma.

Adaptimmune: A pioneer in T-cell therapies, Adaptimmune leverages its expertise in engineered T-cell receptors (TCRs) to develop immunotherapies specifically aimed at synovial sarcoma, such as its SPEAR T-cell platform.

Takara Bio Inc.: Known for its innovative approaches to genetic and cellular therapies, Takara Bio develops products that have potential applications in treating synovial sarcoma and other solid tumors.

Johnson & Johnson: Through its Janssen Pharmaceutical division, Johnson & Johnson is focused on advancing oncology treatments, including immuno-oncology drugs and targeted therapies that could benefit synovial sarcoma patients.

F. Hoffmann-La Roche Ltd.: Roche is a global leader in cancer research and therapy development. Its targeted therapies and advancements in personalized medicine could provide new treatment options for synovial sarcoma.

Eisai Co., Ltd.: This Japanese pharmaceutical company is heavily invested in oncology, with research focused on precision medicine and new therapies targeting rare cancers, including synovial sarcoma.

Aadi Biosciences: Specializes in mTOR inhibitors, with a focus on rare cancers. Aadi Biosciences’ targeted therapies could offer innovative solutions for managing synovial sarcoma.

Immunocore Ltd.: A leader in T-cell receptor-based therapies, Immunocore develops cutting-edge immunotherapies that could address synovial sarcoma’s unique molecular profile.

GlaxoSmithKline (GSK): A major pharmaceutical company with a robust oncology pipeline, GSK is exploring therapies that harness the immune system to combat cancers like synovial sarcoma.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/synovial-sarcoma-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5121

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 13, 2024
Ulcerative Colitis Treatment Market Key Players and Industry Insights
Ulcerative Colitis Treatment Market Key Insights and Trends

The fight against ulcerative colitis is advancing, with the treatment market valued at USD 10.16 billion in 2023. The market is on a steady growth trajectory, projected to exceed USD 14 billion by 2033 at a compound annual growth rate (CAGR) of 4.1%.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5118

The National Library of Medicine estimates that ulcerative colitis affects 9 to 20 people per 100,000 annually, with a total prevalence ranging from 156 to 291 cases per 100,000. These numbers highlight the increasing need for effective treatment options for managing this condition.

Ulcerative colitis is a chronic disease that causes inflammation and sores in the inner lining of the large intestine and rectum. The exact cause remains unclear, but it is believed to involve a combination of genetic, environmental, and immune system factors. This condition is common worldwide and primarily affects the lower part of the large intestine, moving upward.

During flare-ups, symptoms can include abdominal pain, watery or bloody diarrhea, rectal bleeding, an urgent need for bowel movements, fatigue, weight loss, and fever. The disease often follows a pattern of remission and relapse, with symptom-free periods followed by episodes of discomfort.

Treatment focuses on reducing inflammation, managing symptoms, and improving quality of life. Approaches may include medications, dietary adjustments, lifestyle changes, and, in some cases, surgery. In the United States, managing ulcerative colitis is a significant healthcare burden, requiring frequent medical care and incurring substantial costs. This long-term condition can impact both physical health and emotional well-being.

The figure below illustrates how inflammatory bowel diseases (IBDs), including ulcerative colitis (UC), Crohn’s disease (CD), and unclassified IBD (IBDU), are diagnosed across different age groups, based on an MDPI study.

Leading Companies in the Ulcerative Colitis Treatment Market

The ulcerative colitis treatment market is shaped by major pharmaceutical players developing innovative therapies to address this chronic condition.
- AbbVie: A leader in biologics, particularly with its blockbuster anti-inflammatory drugs.
- Takeda Pharmaceuticals: Renowned for its advancements in gastroenterology, including ulcerative colitis treatments.
- Johnson & Johnson Services, Inc.: A key player with a diversified portfolio in immunology and inflammatory bowel disease.
- Pfizer: Offers cutting-edge biologics and small-molecule therapies for inflammatory conditions.
- Bristol Myers Squibb: Focused on immune-modulating treatments, driving progress in ulcerative colitis care.
- Merck & Co.: A global powerhouse contributing to innovative solutions for autoimmune disorders.
- Ferring Pharmaceuticals: Specializes in gastroenterology, offering targeted therapies for digestive diseases.
- Sanofi: A prominent name in immunology, actively expanding its pipeline for inflammatory diseases.
- Novartis: Known for leveraging advanced technologies to develop treatments for chronic conditions like ulcerative colitis.
- Bausch Health: Provides accessible therapies with a focus on improving the quality of life for patients.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/ulcerative-colitis-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5118

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 13, 2024
Thermostable Vaccine Market Innovations, Trends and Global Impact
Thermostable Vaccines A Game-Changer

Thermostable vaccines could replace up to 20% of the global vaccine market within the next decade.

In 2021, WHO reported 94 vaccine distributors globally, with China (23) and India (7) leading the Western Pacific region, representing 32% of its manufacturers. Overall, 41% of vaccine producers were based in this region.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5117

The Promise of Thermostable Vaccines

The World Health Organization (WHO) estimates that immunization saves 3.5–5 million lives annually by preventing diseases like diphtheria, tetanus, pertussis, influenza, and measles. However, cold storage challenges often lead to vaccine damage, limiting their effectiveness. Thermostable vaccines offer a breakthrough by remaining stable at room temperature for extended periods, eliminating the need for costly cold chain logistics. This innovation reduces storage and transportation expenses, making large-scale immunization efforts more affordable and accessible.

Unlike traditional vaccines that require strict refrigeration to retain their potency, thermostable vaccines are designed to withstand temperature fluctuations. This is particularly valuable in regions with limited refrigeration infrastructure, such as remote areas or during emergencies. By overcoming logistical hurdles, thermostable vaccines expand access to life-saving immunizations, ensuring that underserved communities can benefit from vaccination programs.

Tuberculosis (TB) remains a significant global health challenge, spreading through the air when infected individuals breathe out bacteria. In 2021, TB caused 1.6 million deaths and affected 10.6 million people, with nearly two billion people carrying TB bacteria. Thermostable vaccines could play a vital role in managing this disease, especially in areas with inadequate refrigeration.

Recent Progress

In March 2023, the Access to Advanced Health Institute (AAHI) announced promising results from a Phase I clinical trial for a novel thermostable TB vaccine. This vaccine targets Mycobacterium tuberculosis, the bacteria responsible for TB, using a fusion protein (ID93) combined with a specialized immune-boosting adjuvant (GLA-SE). Presented in a freeze-dried form, the vaccine does not require refrigeration, making it a game-changer in TB prevention and control.

Vaccines with Improved Thermal Stability

While there are no FDA-approved vaccines that are entirely thermostable and free from refrigeration requirements, some vaccines have been developed with enhanced thermal stability. These vaccines can tolerate higher temperatures for longer periods without losing effectiveness, making them more practical for areas with limited refrigeration access.
- The Rotavirus vaccine (RIX4V) remains effective for up to 24 months at room temperature (up to 77°F).
- The Meningococcal conjugate vaccine (Menveo) stays stable for 3 months without refrigeration.
- The Measles, mumps, and rubella vaccine (MMR II) retains its potency for 3 days at room temperature.
- The Zoster vaccine (SHINGRIX) can maintain stability for 25 days when stored at room temperature.
Thermostable vaccines are a major step forward in vaccine technology. By reducing dependence on cold chain logistics, they address storage and transportation challenges, improving global vaccination efforts. These advancements ensure vaccines remain effective in difficult conditions, helping to protect more people from preventable diseases and advancing global public health.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/thermostable-vaccine-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5117

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 13, 2024
RNAi Therapeutics Market: Recent Developments and Key Players
RNAi Therapeutics Market Growth and Trends
The RNA interference (RNAi) therapeutics market, which was once a specialized area, is now experiencing rapid growth. In 2023, the market reached USD 1.11 billion and is projected to expand significantly, with an impressive compound annual growth rate (CAGR) of 14.9%. By 2033, the market is expected to surge to USD 4.28 billion.

Small interfering RNA (siRNA) therapy is leading the way, accounting for 64% of the market share in 2023. Cancer treatment remains a key focus, with oncology applications set to dominate the market throughout the forecast period. North America was the leading region, holding a substantial 41% share of the market in 2023.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5115

Emerging Trends and Recent Changes in RNAi Therapeutics

RNA interference (RNAi) therapeutics started to gain momentum in clinical trials after 2008, a decade after the RNAi mechanism was first discovered. Since then, the number of clinical trials using RNAi-based drugs has grown significantly. From 2008 to 2022, the number of published clinical trials in this field increased nearly tenfold, and the number of ongoing trials surged about seven times between 2015 and 2021.

However, there was a noticeable decline in 2022, with a nearly 40% drop in ongoing trials involving small interfering RNA (siRNA) drugs. Despite this setback, siRNAs remain the dominant RNAi molecule used in clinical trials. In 2022, siRNAs made up about 90% of both published and ongoing trials, and this trend has continued into 2023, with nearly all current studies focusing on siRNA-based therapies.

In contrast, short hairpin RNAs (shRNAs) have been used less frequently but have maintained a steady presence in clinical trials over the years. Research involving shRNA-based treatments remains small but consistent. Similarly, studies exploring microRNAs (miRNAs) and miR-shRNAs are limited, with only a few publications and ongoing investigations in this area.

Recent Developments

In January 2023, the US FDA granted Breakthrough Therapy designation to Moderna’s new mRNA vaccine, mRNA-1345. This vaccine is designed to protect adults aged 60 and older from respiratory diseases caused by RSV infection.

In September 2022, Alnylam Pharmaceuticals, Inc. received approval from the European Commission to market their RNAi therapy, AMVUTTRA. This treatment is intended for adults with hereditary transthyretin-mediated (hATTR) polyneuropathy in stage 1 or stage 2.

Key Companies in the RNAi Therapeutics Market

Alnylam Pharmaceuticals, Inc.

Novartis

Arbutus Biopharma

Arrowhead Pharmaceuticals

Novo Nordisk (Dicerna Pharmaceuticals)

Sirnaomics

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/rnai-therapeutics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5115

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 12, 2024
Retinitis Pigmentosa Market Key Trends, Developments and Future Outlook
Retinitis Pigmentosa Market Overview Growth and Emerging Opportunities

The global retinitis pigmentosa (RP) market was valued at USD 14.02 billion in 2023 and is expected to grow significantly, reaching USD 21.40 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 6.2% from 2023 to 2033.

In 2023, autosomal recessive RP was the dominant form, accounting for 65% of the market share. However, gene therapy is gaining attention, with a promising 23% market share, offering new hope for many patients.

Currently, North America holds the largest share of the RP market, but Asia Pacific is experiencing the fastest growth, potentially reshaping the market’s future dynamics.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5114

In 2022, it was estimated that between 82,500 and 110,000 people in the United States were living with retinitis pigmentosa (RP), highlighting the increasing need for new treatments, such as gene therapy and retinal implants.

Retinitis pigmentosa refers to a group of genetic eye disorders that affect the retina, the part of the eye responsible for vision. The condition causes the gradual deterioration of photoreceptor cells, which are essential for seeing in different lighting conditions and maintaining clear vision. As RP progresses, people often experience difficulty seeing in low-light or at night, a loss of peripheral vision, and, in some cases, complete blindness.

There are two main types of retinitis pigmentosa: non-syndromic and syndromic. Non-syndromic RP, which accounts for 70-80% of cases, does not involve other systemic health issues. On the other hand, syndromic RP, which makes up 20-30% of cases, is linked to additional health conditions outside of the eyes. Non-syndromic RP is caused by mutations in about 80 different genes, with 20% of cases being autosomal recessive, 10-20% autosomal dominant (AD), and 10% X-linked recessive.

A 2021 study by the National Institutes of Health, conducted in Spain (which has one of the largest patient populations for inherited retinal diseases), also found new insights into X-linked retinitis pigmentosa (XLRP). While it was previously thought that only males were affected by XLRP, it is now recognized that female carriers can also show symptoms, ranging from mild to severe retinal disease. The remaining cases of RP are considered “sporadic,” meaning no clear inheritance pattern or molecular cause has been identified.

Recent Developments in Retinitis Pigmentosa Treatment

In January 2022, 4D Molecular Therapeutics announced that the FDA had granted special status to 4D-125, a promising treatment for X-linked retinitis pigmentosa (XLRP). This therapy is designed to deliver a functional version of the RPGR gene directly to the retina’s light-sensitive cells and is formulated for easy administration into the eye.

Also in 2022, Bionic Vision Technologies (BVT) received Breakthrough Device designation from the FDA for their Bionic Eye System. This recognition marks a major step forward in the field of bionic vision technology, with the system offering hope for people with severe vision impairments.

In the Netherlands, a patient underwent the first procedure to receive the Prima System, a bionic eye implant developed by Pixium Vision in France. This innovative implant holds promise for people suffering from geographic atrophy (GA), a form of dry age-related macular degeneration (AMD), offering the potential for partial vision restoration.

Key Companies in the Retinitis Pigmentosa Market
- Novartis: A global healthcare company involved in developing treatments for a range of eye diseases, including retinitis pigmentosa.
- Roche (Spark Therapeutics Inc.): Known for its gene therapy solutions, Spark Therapeutics is making strides in addressing genetic eye diseases like retinitis pigmentosa.
- MeiraDx: A biotechnology firm focused on the development of diagnostic and therapeutic products for various retinal conditions.
- Astellas Pharma Inc.: A leading pharmaceutical company investing in gene therapy research and development for retinal diseases.
- Clino Corporation: A biotechnology company focused on rare genetic diseases, including retinitis pigmentosa.
- Gensight Biologics: A clinical-stage biotechnology company working on gene therapies aimed at treating retinal degenerative diseases like RP.
- InFlectis BioScience: A company focused on developing therapies for ocular diseases, including retinitis pigmentosa, with a focus on gene therapy.
- Bausch Health Companies Inc.: A global healthcare company with a growing portfolio of treatments for eye conditions, including those affecting the retina.
- Adverum Biotechnologies: A biotechnology company developing gene therapies for retinal diseases, including a potential treatment for RP.
- ReGenx Biosciences: A biotechnology company specializing in gene therapies for genetic disorders, including retinitis pigmentosa.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/retinitis-pigmentosa-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5114

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 12, 2024
Advanced Drug Delivery Market Recent Developments and Key Players
Advanced Drug Delivery Market Insights

The advanced drug delivery market experienced significant growth in 2023, reaching a value of USD 234.84 billion. Projections indicate that the market will expand to USD 375.86 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.6% over the forecast period from 2023 to 2033.

Oral drug delivery systems were the leading segment in 2023, accounting for 48% of the market share. Controlled release technologies also played a pivotal role, securing 42% of the market.

North America dominated the market in 2023, holding 38% of the global share. However, Asia Pacific is anticipated to be the fastest-growing region, with a projected CAGR of 7.4%.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5113

In 2022, the World Health Organization reported approximately 630,000 deaths from HIV-related causes, emphasizing the urgent need for better treatments. Advanced drug delivery methods are emerging as a promising solution to manage infectious diseases like HIV, offering new ways to treat patients and improve their outcomes.

The advanced drug delivery market includes various technologies designed to deliver drugs or biologics into the body more precisely, efficiently, and with greater control. These systems aim to maximize the therapeutic effect of medications while minimizing side effects and improving patient adherence. They use techniques like nanotechnology, microencapsulation, targeted drug delivery, and controlled-release systems.

Advanced drug delivery plays a vital role in modern medicine for several reasons. One key benefit is the ability to target drugs directly to specific tissues or cells, enhancing the treatment’s effectiveness while reducing side effects. This targeted delivery leads to better results with fewer unwanted reactions. Additionally, controlled-release systems allow for longer-lasting effects of medications, meaning patients don’t need to take their doses as often, making it easier for them to stick to their treatment plans.

These systems also help minimize off-target effects, improving patient comfort and safety. By reducing side effects, the treatment process becomes more tolerable, contributing to a better overall experience for the patient. Furthermore, some drug delivery systems can improve the bioavailability of drugs, ensuring that a higher portion of the drug reaches its target, thereby optimizing its effectiveness.

Advanced drug delivery technologies also allow for more personalized treatments. These systems can be tailored to meet the specific needs of individual patients, enabling healthcare providers to develop more effective and customized treatment strategies. In conclusion, advanced drug delivery systems represent a major step forward in medicine, offering better efficacy, safety, patient compliance, and personalized care.

Recent Developments

In March 2022, Corium, Inc. received approval from the U.S. Food and Drug Administration (FDA) for its ADLARITY (donepezil transdermal system). This treatment is designed for patients with mild to severe Alzheimer’s-type dementia and is one of the first patches to deliver a consistent dose of donepezil through the skin once a week.

In the same month, the FDA also approved the first generic version of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. This inhaler is used to treat two common lung conditions— asthma in patients aged six and older, and chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.

Key Companies in the Advanced Drug Delivery Market
- Pfizer
- Boston Scientific Corporation
- AbbVie
- Baxter
- Kindeva Drug Delivery
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Takeda Pharmaceutical Company Limited
- Novartis
- AstraZeneca
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/advanced-drug-delivery-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5113

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 12, 2024
Telehealth and Telemedicine Market Report Transforming Healthcare Delivery and Driving Global Growth
Telehealth and Telemedicine Market Key Highlights

The telehealth and telemedicine market reached USD 214.55 billion in 2023 and is projected to hit USD 869.22 billion by 2033, growing at a 15.5% CAGR.

Software and services led with a 71% market share, while cloud-based delivery dominated at 67%. Telemedicine platforms captured 45% of the market, with chronic disease management accounting for 30%.

Asia Pacific stands out with a forecasted 27.5% CAGR, showcasing immense growth potential.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5112

The Impact of Telemedicine: Expanding Access, Cutting Costs, and Improving Care

Telemedicine is reshaping healthcare delivery in profound ways:
- Better Access: An impressive 93% of telemedicine solutions have improved patient access to care. Regardless of location, mobility, or time constraints, patients can now connect with medical professionals more easily.
- Enhanced Efficiency: 77% of telemedicine platforms help doctors and patients save time. Virtual consultations eliminate travel and waiting times, allowing doctors to serve more patients in less time.
- Cost Savings: 71% of telemedicine services help lower healthcare costs by reducing hospital visits, travel expenses, and lost work time, benefitting both patients and providers.
- Improved Communication: 71% of telemedicine tools enhance doctor-patient communication. Video calls, messaging, and image sharing foster more effective interactions and consultations.
- Stronger Relationships: 60% of telemedicine platforms help build better doctor-patient relationships. Frequent and convenient virtual interactions strengthen trust and understanding.
Overall, telemedicine is transforming healthcare by making it more accessible, efficient, and cost-effective, while improving communication and fostering stronger patient-doctor relationships.

Regional Insights
- North America: The region leads the global telehealth market, driven by advanced technological infrastructure, high healthcare spending, and supportive regulations. The COVID-19 pandemic accelerated telehealth adoption, spurring investment in digital health solutions and wider acceptance of remote care.
- Europe: Aging populations, rising healthcare costs, and the demand for chronic disease management are fueling telehealth growth. Countries like the UK, Germany, and France are expanding remote healthcare access and integrating telemedicine into their systems.
- Asia-Pacific: This region is set for rapid growth due to increasing smartphone usage, better internet connectivity, and rising healthcare needs in rural areas. Investments in telehealth by countries like China, India, Japan, and South Korea aim to overcome access barriers and improve health outcomes.
Competitive Landscape

The telehealth market is highly dynamic, with a mix of established healthcare providers, tech companies, and startups. Hospitals, clinics, and practices are increasingly adopting telemedicine to offer virtual consultations, remote monitoring, and digital health services across specialties like primary care, mental health, and chronic disease management. Insurers are also broadening coverage for these services, reflecting telehealth’s growing acceptance.

Recent Industry Developments
- In June 2022, GoMeyra introduced GoVirtual Clinic, a cloud-based telehealth platform for secure consultations and remote medical testing.
- In December 2023, Babylon Health partnered with Amazon to expand global access to virtual healthcare services.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/telehealth-and-telemedicine-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5112

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 12, 2024
Corticosteroids Market Trends and Growth Outlook
Corticosteroids Market Overview

The corticosteroids market was valued at USD 4.71 billion in 2023 and is projected to reach USD 6.91 billion by 2033, growing at a 4.2% CAGR.

Rheumatology led with 35% market share in 2023, while dermatology is the fastest-growing segment, boasting a 5.1% CAGR. Topical corticosteroids dominated the market, holding 49% of the share.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5111

Understanding Corticosteroids Key Insights and Applications

The Forum of International Respiratory Societies estimates that over 4.5 million lives have been lost due to the ongoing pandemic, with respiratory issues being the primary cause. During this crisis, corticosteroids have played a crucial role in treating respiratory diseases.

Corticosteroids are steroid hormones naturally produced by the adrenal cortex, located on top of each kidney. These hormones regulate essential processes such as metabolism, immune response, and electrolyte balance. They are categorized into two main types:
- Glucocorticoids: Hormones like cortisol that regulate metabolism and the immune system.
- Mineralocorticoids: Hormones like aldosterone that help maintain electrolyte and water balance.
In medicine, synthetic corticosteroids are widely used for their anti-inflammatory and immunosuppressive properties. Available as oral tablets, topical creams, inhalers, and injections, they are prescribed to manage a variety of conditions, including autoimmune disorders, allergies, asthma, inflammatory joint diseases, and skin conditions.

Healthcare providers carefully monitor corticosteroid use to minimize potential side effects such as bone loss, immune suppression, and metabolic disturbances. Treatment plans are tailored to ensure the benefits outweigh the risks, with dosages adjusted based on individual needs.

The rising prevalence of respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD) has driven up demand for inhaled corticosteroids as part of their treatment. Additionally, corticosteroids play a role in cancer care, helping manage chemotherapy side effects. As cancer treatments evolve, the demand for supportive medications like corticosteroids is expected to grow.

With their versatile applications and significant role in managing various health conditions, corticosteroids remain a cornerstone in modern medical treatment.

Recent Developments in the Corticosteroids Market
- August 2022: ReveraGen BioPharma initiated a study to evaluate Vamorolone for treating Becker muscular dystrophy (BMD). In this trial, the first patient received a dose of nandrolone, marking a significant step toward exploring this steroid’s potential as a treatment for various muscular dystrophies.
- April 2022: Eli Lilly and Company tested a combination of Lebrikizumab and topical corticosteroids to treat atopic dermatitis (AD), a chronic skin condition. After 16 weeks, patients showed a remarkable 75% improvement. The combination effectively addressed key symptoms like skin inflammation and itching, offering hope for better AD management.
Leading Companies in the Corticosteroids Market
- Pfizer
- Novartis
- Merck & Co., Inc.
- GlaxoSmithKline
- AstraZeneca
- Bausch Health Companies Inc.
- Galderma
- Cipla
- Sanofi
- Teva Pharmaceutical Industries Ltd.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/corticosteroids-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5111

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
December 12, 2024